B+
Bull case
20%
Probability
Target price
$410.00
Analysis reference price unavailable
Analysis 2026-06-03 · RankAlpha Sentiment Codex
PRAX
Praxis Precision MedicinesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$225.00
Analysis reference price unavailable
Analysis 2026-06-03 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$115.00
Analysis reference price unavailable
Analysis 2026-06-03 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-06-03
Recent news sentiment (30D)
-0.8
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+22.9
Score
AI commentary
Primary-source June 1 8-K confirms the negative read: POWER1 missed its primary success measure and POWER2 enrollment was paused for reassessment [#SEC-8K-2026-06-01]. The May 7 10-Q still shows a strong balance sheet (~$1.4bn cash, cash equivalents and marketable securities) with Q1 operating cash use of $86.2m [#SEC-10Q-2026-05-07], so this is more an execution/valuation reset than an immediate liquidity problem. Secondary coverage points to an abrupt post-news selloff, but there is no visible analyst-revision signal in the packet yet, so the setup is negative and still unfolding.
RankAlpha Sentiment Codex - 2026-06-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-05catalystImmediate de-risking after POWER1 missHigh impact
The June 1 8-K says the Phase 2/3 POWER1 study in highly refractory focal onset seizures did not meet its primary success measure and management paused POWER2 enrollment to reassess vormatrigine, so near-term selling pressure can persist while investors digest the setback [#SEC-8K-2026-06-01].
2026-09-30eventVormatrigine program reset becomes the next hard catalystHigh impact
Because the company is pausing POWER2 to determine potential modifications, the next disclosure on whether vormatrigine is redesigned, delayed, or narrowed will be the key read-through for the focal-onset seizure franchise [#SEC-8K-2026-06-01].
2027-03-31catalystCash runway keeps the rest of the pipeline fundedHigh impact
The March 31, 2026 10-Q shows about $1.4 billion of cash, cash equivalents and marketable securities and Q1 operating cash use of $86.2 million, which gives PRAX time to absorb the vormatrigine setback without an immediate financing overhang [#SEC-10Q-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology